Frontlight ResearchEarly access
CompletedNo phase
CEFID-II (CEra Flow Improves DVT-II)
Key facts
- Who runs it
- Ceragem Clinical Inc.
- Where
- South Korea3 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 60 people enrolled
- Started
- 22 Dec 2022
- Ended
- 28 Oct 2024
- Type of study
- Interventional
- Treatments tested
- Blood circulation device
- Record updated
- 5 February 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Adult men and women over 19 years of age
- Subjects who have not been diagnosed with deep vein thrombosis in the lower extremities through the following test results prior to the application of medical devices; (1) Subjects diagnosed by Doppler ultrasonography as having no blood clots in the femoral vein and the vena poplitea (2) D-dimer negative test result (Even if D-dimer is tested positive, it can be selected through additional tests at the discretion of investigator.)
- Subjects have 2 or more points of venous thromboembolism (hereinafter referred to as VTE) clinical prediction score (Two-level wells score) at the time of screening
- Subjects who fully understand the purpose and procedure of the study and wish to participate in clinical trials with voluntary consent
Who cannot take part
- Subjects complain of a decrease in the sensation of the lower extremities or is unable to feel the sensation of pain
- Subjects have inflammation or trauma on the skin that directly touches the device
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
For Deep Vein Thrombosis (DVT) risk groups, the effect and safety of blood circulation improvement before and after application are evaluated using an investigational device (model name CGM MB-1701).
The group in the trial
- blood circulation treatmentTreatment being tested
Blood circulation treatment for the risk group for Deep Vein Thrombosis (DVT)
Treatment: Blood circulation device
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multiple Center, Clinical Trial to Evaluate the Efficacy and Safety of Blood Circulation Improvement Using an Investigational Device (Model Name CGM MB-1701) for the Risk Group of Deep Vein Thrombosis (DVT)
- Record updated
- 5 February 2026